

Metabolic Changes in Diabetes Mellitus

Dr. Sumbul Fatma

*Clinical Chemistry Unit, Pathology Dept.
College of Medicine, King Saud University*

Lecture outlines

▶ Background

- Differences between type 1 and type 2 DM
- Natural course of T1DM
- Natural course of T2DM

▶ Diagnostic criteria for DM

▶ Metabolic changes in DM


- Increase of hepatic glucose output
- Decrease of glucose uptake
- Inter-organ relationship in T1DM and T2DM

▶ Mechanisms of diabetic complications


Comparison of type 1 and type 2 DM

	Type 1 Diabetes	Type 2 Diabetes
AGE OF ONSET	Usually during childhood or puberty; symptoms develop rapidly	Frequently after age 35; symptoms develop gradually
NUTRITIONAL STATUS AT TIME OF DISEASE ONSET	Frequently undernourished	Obesity usually present
PREVALENCE	900,000 = 10% of diagnosed diabetics	10 Million = 90% of diagnosed diabetics
GENETIC PREDISPOSITION	Moderate	Very strong
DEFECT OR DEFICIENCY	β Cells are destroyed, eliminating production of insulin	Insulin resistance combined with inability of β cells to produce appropriate quantities of insulin
FREQUENCY OF KETOSIS	Common	Rare
PLASMA INSULIN	Low to absent	High early in disease; low in disease of long duration
ACUTE COMPLICATIONS	Ketoacidosis	Hyperosmolar coma
TREATMENT WITH ORAL HYPOGLYCEMIC DRUGS	Unresponsive	Responsive
TREATMENT	Insulin is always necessary	Diet, exercise, oral hypoglycemic drugs, +/- insulin

Natural course of T1DM



Progression of T2DM



Criteria for Diagnosis of DM*

Categories of increased risk for diabetes*

FPG 100-125 mg/dL (5.6-6.9 mmol/L) [IFG]
2-h PG on the 75-g OGTT 140-199 mg/dL (7.8-11.0 mmol/L) [IGT]
A1C 5.7-6.4 percent

FPG: fasting plasma glucose; IFG: impaired fasting glucose; PG: post glucose; OGTT: oral glucose tolerance test; IGT: impaired glucose tolerance; A1C: glycated hemoglobin.

Criteria for the diagnosis of diabetes

1. A1C ≥ 6.5 percent. The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.*

OR

2. FPG ≥ 126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h.*

OR

3. Two-hour plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during an OGTT. The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.*

OR

4. In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥ 200 mg/dL (11.1 mmol/L).

A1C: glycated hemoglobin; NGSP: National glycohemoglobin standardization program; DCCT: Diabetes control and complications trial; FPG: fasting plasma glucose; OGTT: oral glucose tolerance test.

* In the absence of unequivocal hyperglycemia, criteria 1-3 should be confirmed by repeat testing.

Reprinted with permission from: American Diabetes Association. Standards of Medical Care in Diabetes Care 2010; 33:S11.

Copyright © 2010 American Diabetes Association.

***American Diabetes Association (ADA), 2010**


HEMOGLOBIN A1C

- ▶ Hemoglobin A1C (A1C) is the result of non enzymatic covalent glycosylation of hemoglobin
- ▶ It is used to estimate glycemic control in the last 1–2 months
- ▶ Recently, A1C is recommended for the detection of T2DM
- ▶ A1C and fasting plasma glucose (FPG) were found to be similarly effective in diagnosing diabetes.
- ▶ A1C cut-off point of $>6.5\%$ is used to diagnose diabetes.
- ▶ A1C values also correlate with the prevalence of retinopathy
- ▶ Assays for A1C has to be standardized according to the National Glycohemoglobin Standardization Program (NGSP).


Metabolic Effects of Diabetes Mellitus

- ▶ **Absolute or relative insulin deficiency →**
 1. ↓ **Glucose uptake (muscle & adipose tissue)**
 2. ↑ **Glucose production (liver)**

Intertissue Relationship in T1DM



Intertissue Relationship in T2DM




Major Metabolic changes in DM

Absolute or relative insulin deficiency



Multiple metabolic effects



Mechanisms of Increase Hepatic Glucose Output

↓ Insulin



↓ Inhibitory effect on glucagon secretion



↑ Glucagon



↑ Gluconeogenesis & glycogenolysis
(Liver)



↑ Plasma glucose

Mechanisms of Decrease of Peripheral Glucose Uptake

Muscle

↓ Insulin



↓ Glucose & amino acid uptake
↑ Protein breakdown



↑ Plasma glucose
↑ Plasma amino acids

Adipose Tissue

↓ Insulin



↓ Glucose uptake




↑ Plasma glucose

Mechanisms of Diabetic Complications



Typical Progression of T2DM



General Mechanisms for Diabetic Microvascular Complications

Chronic hyperglycemia →

- 1. ↑ AGEs of essential cellular proteins → cellular defects**
- 2. ↑ Intracellular sorbitol → ↑ cell osmolality → cellular swelling**
- 3. ↑ ROS → oxidative stress → cell damage**

Advanced Glycosylation End Products (AGEs)



- ▶ Chronic hyperglycemia → non-enzymatic combination between excess glucose & amino acids in proteins → formation of AGEs
- ▶ AGEs may cross link with collagen → microvascular complications
- ▶ The interaction between AGEs and their receptor (RAGE) may generate reactive oxygen species (ROS) → inflammation

Polyol pathway

- ▶ Glucose is metabolized to sorbitol within the cells by aldose reductase
- ▶ The role of sorbitol in the pathogenesis of diabetic complications is uncertain. Hypotheses are:
 - During sorbitol production, consumption of NADPH → oxidative stress.
 - Sorbitol accumulation →
 - Increase the intracellular osmotic pressure → osmotic drag of fluid from extracellular space → cell swelling
 - Alteration in the activity of PKC → altered VEGF activity → altered vascular permeability

Sorbitol Metabolism Polyol Pathway

A Mechanism for Diabetic Complications



Diabetic Retinopathy

- ▶ A progressive microvascular complication of DM, affecting the retina of the eye
- ▶ A major cause of morbidity in DM (→ **blindness**)
- ▶ Its prevalence ↑ with increasing duration of disease in both type 1 & 2 DM
- ▶ After **20 years** of the disease:
 - Is present in almost **all** T1DM
 - Is present in **50 – 80%** of T2DM

Diabetic Nephropathy

- ▶ Occurs in both type 1 & type 2 DM
- ▶ The earliest clinical finding of diabetic nephropathy is **microalbuminuria**:
 - ▶ (the persistent excretion of small amounts of albumin (30–300 mg per day) into the urine)
- ▶ Microalbuminuria is an important predictor of progression to **proteinuria**:
 - (the persistent excretion of >300 mg albumin per day into the urine)
- ▶ Once proteinuria appears, there is a steady ↓ in the glomerular filtration rate (GFR)
- ▶ Finally, **end-stage renal disease** occurs

Sequence of Events in Diabetic Nephropathy

Glomerular hyperfiltration



Microalbuminuria



Proteinuria & ↓ GFR




End-stage renal disease

Diabetic Neuropathy

- ▶ Loss of both myelinated and unmyelinated nerve fibers
 - ▶ Occurs in both type 1 & type 2 DM
 - ▶ It correlates with the duration of DM & with glycemic control
- 

THANK YOU

The bottom of the slide features a decorative graphic consisting of several overlapping, wavy shapes. On the left, there is a large, dark blue shape that tapers towards the right. Overlapping this is a lighter blue shape that also tapers. At the bottom right, there is a solid black shape that fits into the curve of the other shapes.